Hospital.Help

Berlin – The current treatment options for post-COVID syndrome (PCS) are primarily symptomatic and off-label. However, there are currently some studies underway in Germany that offer hope for new treatment options. Carmen Scheibebogen, head of the immunodeficiency clinic at the Charité, reported this yesterday at the 3rd Long COVID Congress. According to Scheibebogen, the greatest hope is medicines that produce antibodies…